Summary

Global Pneumococcal Vaccine Market was valued at USD 9.63 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.26% through 2030. The global pneumococcal vaccine market is a crucial segment of the pharmaceutical and healthcare industry, primarily aimed at preventing infections caused by Streptococcus pneumoniae bacteria. Pneumococcal infections can lead to various illnesses, including pneumonia, meningitis, and sepsis, and they pose a significant public health threat, particularly to young children and the elderly. For instance, according to WHO estimates in 2023, pneumococcal infections cause approximately 1.6 million deaths worldwide each year, with nearly one million fatalities occurring in children under the age of five. Given its significant impact on child mortality, WHO classifies pneumococcal disease as a high-priority condition for vaccination. To combat this, the organization strongly recommends the use of 13-valent pneumococcal conjugate vaccines (PCVs) as an effective preventive measure. These vaccines play a crucial role in reducing severe infections such as pneumonia, meningitis, and sepsis in young children, particularly in regions with limited healthcare access and high disease prevalence.
Key Market Drivers
Rising Global Awareness of Pneumococcal Diseases
One of the fundamental reasons behind the growth of the pneumococcal vaccine market is the increasing understanding of the serious health consequences posed by pneumococcal diseases. Medical professionals, policymakers, and the general public are becoming more aware of the debilitating and potentially fatal nature of these infections, leading to a heightened sense of urgency in preventing them. For instance, in June 2023, Sanofi and SK bioscience announced positive results from phase II clinical trials of their 21-valent conjugate vaccine candidate. The findings suggest that GBP410 may provide broader serotype coverage compared to existing vaccines, potentially expanding its market share. Based on these promising results, the companies plan to advance to phase III trials in 2024, with the goal of obtaining final data by 2027.
Public health organizations and advocacy groups have played a pivotal role in disseminating information about pneumococcal diseases. Their efforts include educational campaigns, public service announcements, and initiatives that emphasize the importance of vaccination. As individuals become better informed, they are more likely to seek out and request pneumococcal vaccines.
Key Market Challenges
Economic Disparities
One of the most prominent challenges is the economic disparity among nations. High-income countries often have better access to pneumococcal vaccines due to robust healthcare infrastructures and funding. In contrast, low- and middle-income countries struggle to afford these vaccines, leading to unequal access and health disparities.
Key Market Trends
Next-Generation Vaccines
Advancements in vaccine technology are paving the way for next-generation pneumococcal vaccines. These vaccines are designed to offer broader protection against a wider range of pneumococcal serotypes. By harnessing innovative formulations and targeting evolving bacterial strains, next-gen vaccines are poised to enhance vaccine effectiveness and durability.
Key Market Players
• GSK PLC
• Pfizer Inc
• Merck KGaA
• Serum Institute of India Pvt Ltd
• CSL Ltd
• Sanofi SA
• Walvax Biotechnology Co., Ltd
• Beijing Minhai Biotechnology Limited Company
• AstraZeneca PLC
• BioNTech
Report Scope:
In this report, the Global Pneumococcal Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Pneumococcal Vaccine Market, By Type:
o Conjugate Vaccines
o Polysaccharide Vaccines
• Pneumococcal Vaccine Market, By Indication:
o Bronchitis
o Meningitis
o Pneumonia
o Sepsis
• Pneumococcal Vaccine Market, By Product:
o Pneumovax23
o Prevnar 13
o Synflorix
• Pneumococcal Vaccine Market, By Distribution:
o Government Authorities
o Non-Governmental Organizations
• Pneumococcal Vaccine Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ Germany
§ United Kingdom
§ France
§ Italy
§ Spain
o Asia-Pacific
§ China
§ Japan
§ India
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Pneumococcal Vaccine Market.
Available Customizations:
Global Pneumococcal Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Pneumococcal Vaccine Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
5.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
5.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
5.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Product Market Map
5.3.1. By Type
5.3.2. By Indication
5.3.3. By Product
5.3.4. By Distribution
5.3.5. By Region
6. North America Pneumococcal Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
6.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
6.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
6.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Pneumococcal Vaccine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Indication
6.3.1.2.3. By Product
6.3.1.2.4. By Distribution
6.3.2. Canada Pneumococcal Vaccine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Indication
6.3.2.2.3. By Product
6.3.2.2.4. By Distribution
6.3.3. Mexico Pneumococcal Vaccine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Indication
6.3.3.2.3. By Product
6.3.3.2.4. By Distribution
7. Europe Pneumococcal Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
7.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
7.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
7.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Pneumococcal Vaccine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Indication
7.3.1.2.3. By Product
7.3.1.2.4. By Distribution
7.3.2. United Kingdom Pneumococcal Vaccine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Indication
7.3.2.2.3. By Product
7.3.2.2.4. By Distribution
7.3.3. France Pneumococcal Vaccine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Indication
7.3.3.2.3. By Product
7.3.3.2.4. By Distribution
7.3.4. Italy Pneumococcal Vaccine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Indication
7.3.4.2.3. By Product
7.3.4.2.4. By Distribution
7.3.5. Spain Pneumococcal Vaccine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Indication
7.3.5.2.3. By Product
7.3.5.2.4. By Distribution
8. Asia-Pacific Pneumococcal Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
8.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
8.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
8.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Pneumococcal Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Indication
8.3.1.2.3. By Product
8.3.1.2.4. By Distribution
8.3.2. Japan Pneumococcal Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Indication
8.3.2.2.3. By Product
8.3.2.2.4. By Distribution
8.3.3. India Pneumococcal Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Indication
8.3.3.2.3. By Product
8.3.3.2.4. By Distribution
8.3.4. Australia Pneumococcal Vaccine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Indication
8.3.4.2.3. By Product
8.3.4.2.4. By Distribution
8.3.5. South Korea Pneumococcal Vaccine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Indication
8.3.5.2.3. By Product
8.3.5.2.4. By Distribution
9. South America Pneumococcal Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
9.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
9.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
9.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Pneumococcal Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Indication
9.3.1.2.3. By Product
9.3.1.2.4. By Distribution
9.3.2. Argentina Pneumococcal Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Indication
9.3.2.2.3. By Product
9.3.2.2.4. By Distribution
9.3.3. Colombia Pneumococcal Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Indication
9.3.3.2.3. By Product
9.3.3.2.4. By Distribution
10. Middle East and Africa Pneumococcal Vaccine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
10.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
10.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
10.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Pneumococcal Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Indication
10.3.1.2.3. By Product
10.3.1.2.4. By Distribution
10.3.2. Saudi Arabia Pneumococcal Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Indication
10.3.2.2.3. By Product
10.3.2.2.4. By Distribution
10.3.3. UAE Pneumococcal Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Indication
10.3.3.2.3. By Product
10.3.3.2.4. By Distribution
10.3.4. Kuwait Pneumococcal Vaccine Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Type
10.3.4.2.2. By Indication
10.3.4.2.3. By Product
10.3.4.2.4. By Distribution
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. GSK PLC
14.1.1. Business Overview
14.1.2. Product Offerings
14.1.3. Recent Developments
14.1.4. Financials (As Reported)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. Pfizer Inc
14.3. Merck KGaA
14.4. Serum Institute of India Pvt Ltd
14.5. CSL Ltd
14.6. Sanofi SA
14.7. Walvax Biotechnology Co., Ltd
14.8. Beijing Minhai Biotechnology Limited Company
14.9. AstraZeneca PLC
14.10. BioNTech
15. Strategic Recommendations
16. About Us & Disclaimer